Furthermore, our animal experiments revealed that the application of HDAC8 inhibitors effectively reduced the percentage of CD8+ exhausted T cells in tumor sites and improved the efficacy of anti‐PD‐1 therapy. This evidence concerns the gene PDCD1 and neoplasm.